Hereditary colorectal cancer syndromes are associated with a high risk of developing malignancies. Despite compelling data from preclinical models, clinical studies of promising chemopreventive agents often yield conflicting results. Here, the authors discuss critical issues related to previous chemopreventive trial designs, focusing on common pitfalls and how future interventions might be improved.
- Luigi Ricciardiello
- Dennis J. Ahnen
- Patrick M. Lynch
